EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Opportunities and challenges in applying microbiota to clinical cancer immunotherapy

Dingjiacheng Jia, Liangjing Wang

Trends in Microbiology · 2026-04 · 34 (4) · 367-377

DOI: 10.1016/j.tim.2025.11.011 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Trends in Microbiology, 2026-04. Verfasst von Dingjiacheng Jia und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang Province, 310058, China; Ins…. Hauptthemen laut MEDLINE: Neoplasms, Immunotherapy, Gastrointestinal Microbiome. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 46 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Fundamental research has elucidated the indispensable role of gut microbiota in modulating cancer immunotherapy efficacy. Despite promising preclinical findings, few related approaches have reached clinical trials. In this opinion, we provide insights based on current clinical trials using fecal microbiota transplant or specific bacterial strains as adjuvants to enhance immune checkpoint blockade therapy. We also systematically analyze the challenges in trial design, with a focus on donor selection, patient enrollment, implantation procedures, antibiotic use, safety assessment, and endpoint evaluation. Moving forward, we offer a comprehensive '4D' framework (diversity, diffusion, depth, and delicacy) for accelerating the bench-to-bedside translation. It is hoped that this opinion will help researchers and clinicians aiming to harness microbiome-based strategies to improve cancer immunotherapy outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeoplasmsImmunotherapyGastrointestinal MicrobiomeHumansFecal Microbiota TransplantationClinical Trials as TopicAnimalsImmune Checkpoint Inhibitors

Stichwörter der Autor:innen

cancer immunotherapyclinical trialsfecal microbiota transplantationgut microbiotaimmune checkpoint blockade

Substanzen

Immune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Department of Gastroenterology, Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang Province, 310058, China; Institution of Gastroenterology, Zhejiang University, Hangzhou, Zhejiang…

Zitieren

APA

Jia, D., & Wang, L. (2026). Opportunities and challenges in applying microbiota to clinical cancer immunotherapy. Trends in Microbiology, 34(4), 367-377. https://doi.org/10.1016/j.tim.2025.11.011

Vancouver

Jia D, Wang L. Opportunities and challenges in applying microbiota to clinical cancer immunotherapy. Trends in Microbiology. 2026;34(4):367-377. doi:10.1016/j.tim.2025.11.011

BibTeX
@article{Jia2026,
  author = {Jia, Dingjiacheng and Wang, Liangjing},
  title = {Opportunities and challenges in applying microbiota to clinical cancer immunotherapy},
  journal = {Trends in Microbiology},
  year = {2026},
  volume = {34},
  number = {4},
  pages = {367--377},
  doi = {10.1016/j.tim.2025.11.011}
}
Kostenlos starten →